xport-mf-034: selinexor plus ruxolitinib in jak-inhibitor naïve myelofibrosis
Published 10 months ago • 112 plays • Length 0:46Download video MP4
Download video MP3
Similar videos
-
1:32
genomic evolution & resistance to pirtobrutinib in covalent btk inhibitor pre-treated cll
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
3:10
novel aml treament approaches
-
2:43
gemtuzumab ozogamicin in frontline aml therapy
-
2:12
the prevalence of germline runx1 mutations and their impact on allosct outcomes
-
2:07
phase i/ii study of edit-301, a novel gene-edited autologous hsc medicine, in patients with scd
-
1:59
a strategy for curing cll, one clone at a time
-
0:53
go-flag: bridge therapy to allo-sct in r/r aml
-
7:21
what is crispr?
-
4:36
haemonetics
-
8:36
treating cd33-positive aml with gemtuzumab ozogamicin
-
2:25
low-intensity venetoclax-based salvage as a bridge to allosct in aml
-
6:07
a crispr approach to hematological research
-
2:13
splicing mutations in post-et/post-pv myelofibrosis
-
2:05
investigating mutation order in aml using single-cell sequencing
-
2:48
the novel icaht grading system to predict toxicity following car t-cell therapy
-
3:54
a case study from the ecog-e1910 trial: early blinatumomab treatment in all
-
1:24
investing in education & research for incoming hematology nurses
-
1:49
genomic advancements in non-malignant hematology
-
2:59
low-intensity venetoclax-based preconditioning followed by sequential allosct for r/r aml or hr-mds
-
3:28
the implementation of a data-driven cll-tim algorithm into an epic-based electronic health record
-
1:30
xport-mf-044 trial: evaluating selinexor in jak inhibitor-naïve mf and moderate thrombocytopenia